Dr. Preston D. Steen, MD | Fargo, ND ...

Dr. Preston D. Steen

Claim this profile

Sanford Roger Maris Cancer Center

Expert in Lung Cancer
Expert in Breast Cancer
113 reported clinical trials
192 drugs studied

About Preston D. Steen

Education:

  • Obtained MD from the University of North Dakota School of Medicine & Health Sciences (2015).
  • Completed Residency in Internal Medicine at the University of Minnesota Medical Center (2018).
  • Finished Fellowship in Hematology/Oncology at the Mayo Clinic, Rochester, Minnesota (2021).

Experience:

  • Currently practices as a hematologist and oncologist at Sanford Roger Maris Cancer Center.
  • Specializes in internal medicine, hematology, and oncology.

Area of expertise

1Lung Cancer
Global Leader
Preston D. Steen has run 21 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Preston D. Steen has run 14 trials for Breast Cancer. Some of their research focus areas include:
HER2 positive
Stage IV
ER positive

Affiliated Hospitals

Image of trial facility.
Sanford Roger Maris Cancer Center
Image of trial facility.
Sanford Bismarck Medical Center

Clinical Trials Preston D. Steen is currently running

Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Image of trial facility.

Eribulin + Chemotherapy

for Bladder Cancer

This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.
Recruiting2 awards Phase 3

More about Preston D. Steen

Clinical Trial Related6 years of experience running clinical trials · Led 113 trials as a Principal Investigator · 36 Active Clinical Trials
Treatments Preston D. Steen has experience with
  • Nivolumab
  • Cisplatin
  • Atezolizumab
  • Carboplatin
  • Pembrolizumab
  • Ipilimumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Preston D. Steen specialize in?
Is Preston D. Steen currently recruiting for clinical trials?
Are there any treatments that Preston D. Steen has studied deeply?
What is the best way to schedule an appointment with Preston D. Steen?
What is the office address of Preston D. Steen?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security